<pad> T wo Evidence to Recommendations documents were developed ( https://www.cdc.gov/vaccines/acip/recs/grade/HPV-harmonization-etr.html ) (https://www.cdc.gov/vaccines/acip/recs/grade/HPV-adults-etr.html) (https://www.cdc.gov/vaccines/acip/recs/grade/HPV-adults-etr.html) and presented along with proposed recommendations; after a public com -ment period, ACIP members voted unanimously to harmonize catch-up vaccination recommendations across all persons through age 26 years. ACIP members also voted 10â€“4 in favor of shared clinical decision-making for adults aged 27 through 45 years, recognizing that some persons who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination in this age range.Summary of Key FindingsVaccine efficacy and safety.</s>